India Pharma Outlook Team | Wednesday, 19 August 2026
Fake medicines remain a serious threat to India’s pharmaceutical ecosystem, even as regulators continue to tighten drug-control measures and enforcement.
A fresh raid near Bidadi in Karnataka has exposed how counterfeit products can move beyond illegal manufacturing into repacking, relabeling and potential hospital supply chains.
The Karnataka drug enforcement authorities seized material estimated at Rs 4.91 crore, including thousands of vials, expired medicines, counterfeit labels and packaging equipment.
Reports also indicated that some seized products carried names of major pharmaceutical companies.
The incident highlights a wider challenge for India: protecting patients, legitimate manufacturers and trust in a pharmaceutical supply chain that spans multiple distribution layers.
The Karnataka Food and Drug Administration’s Drug Enforcement Wing conducted a raid at premises near Bidadi in Ramanagara district, southwest of Bengaluru. Officials uncovered a suspected unlicensed operation that allegedly repacked medicines and applied labels associated with reputed pharmaceutical companies.
The seized material carried an estimated value of Rs 4.91 crore, according to reports. Authorities found thousands of vials alongside expired medicines, counterfeit labels, packaging material and equipment used for filling injections. Investigators also recovered invoices and other documentation that could help trace the source and movement of the products.
As per NDTV reports, officials believed the unit sourced medicines from illegal manufacturing facilities in different parts of India before repackaging them under established pharmaceutical names. The investigation has expanded to the wider supply chain, including suppliers and potential buyers. Officials also raised concerns that some products could have been intended for intensive-care use.
Also Read: How Can Indian Pharma Strengthen Quality Amid Rising FDA Scrutiny
The Bidadi case is particularly significant for legitimate pharmaceutical manufacturers. Reports identified labels bearing the names of multinational pharmaceutical companies, including Pfizer, among the seized material. However, the presence of a counterfeit Pfizer label does not indicate any involvement by Pfizer in the production, packaging or distribution of those products. Therefore, this significantly affects the multinational pharmaceutical companies, in areas such as;
1. Brand trust
Counterfeiters can exploit the recognition attached to established pharmaceutical brands. A familiar company name can create an immediate perception of quality and authenticity, making a falsified product appear more credible to buyers.
2. Price arbitrage
NDTV reported that the alleged racket sold counterfeit medicines to hospitals at prices nearly 50 per cent below market rates. This price gap can create an incentive for unscrupulous intermediaries to move products that imitate established brands.
3. Distribution credibility
A recognized brand name can make a counterfeit product appear legitimate as it moves through downstream channels. This creates a particular concern when counterfeiters target products used in hospitals and intensive-care settings.
4. Reputational damage
Counterfeit medicines create a second problem for legitimate manufacturers. Even when a company has no connection to the counterfeit product, patients and healthcare providers may associate a poor treatment outcome or product-quality concern with the genuine brand.
The Bidadi case shows that fake medicines remain a challenge even as India strengthens drug regulation and enforcement. The Rs 4.91 crore seizures also demonstrate that counterfeit activity can involve more than unauthorized manufacturing. Repacking, relabeling, documentation and downstream distribution can create additional points of vulnerability.
For India’s pharmaceutical ecosystem, the priority now extends beyond detecting fake medicines after they enter circulation. Regulators, manufacturers, distributors and healthcare institutions need stronger supply-chain visibility and authentication mechanisms to identify suspicious products earlier.
India’s pharmaceutical industry depends on the credibility of its medicines at home and in global markets. Protecting that credibility requires sustained enforcement, stronger traceability and faster action against counterfeit networks.
